Benedetta Imperiali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Benedetta Imperiali has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Massimiliano Agostini
Department of Experimental Medicine, TOR, University of Rome “Tor Vergata”, Rome, Italy
2 shared publications Alberto Delaidelli
Department of Pathology, Mass General Brigham, Harvard Medical School, Boston, USA
1 shared publication- Alessandro Mauriello
Department of Experimental Medicine, TOR, University of Rome Tor Vergata, Rome, Italy
1 shared publication - Anastasios D. Asimakopoulos
Unit of Urology, Fondazione PTV Policlinico Tor Vergata, Rome, Italy
1 shared publication - Artem Smirnov
Department of Experimental Medicine, TOR, University of Rome “Tor Vergata”, Rome, Italy
1 shared publication - Carlo Ganini
Interdisciplinary Department of Medicine, University of Bari “Aldo Moro”, Bari, Italy
1 shared publication
Latest Publications
- Open Access
- 5 October 2026
- Published by Springer Nature in Cell Death Discovery
Cholesterol esters in lipid droplets play a key role in the energy production of G3/G4 medulloblastoma cells
Medulloblastomas are the most common malignant paediatric brain tumours. High-risk subgroups, including MYC-driven Group 3, Group 4 and aggressive sonic hedgehog tumours, are refractory to current therapies and are associated with poor survival. The gold standard treatment comprises surgical resection with aggressive chemo and radiotherapy leading to severe developmental side effects, highlighting the requirement for novel approaches. Metabolic reprogramming is a crucial component of cancer progression with upregulated lipid metabolism being essential to support cancers survival in nutrient-deprived conditions. Lipid droplets are dynamic intracellular organelles protecting against lipotoxicity, yet their involvement in high-risk Medulloblastoma subgroups remains poorly understood. Here, we use transcriptomics and lipidomics of a panel of Medulloblastoma cells to understand the role of lipid metabolism. Our data shows that high-risk Medulloblastoma cells have increased numbers of lipid droplets and PLIN2 expression. This increased PLIN2 expression was consistent in human tissue microarray analysis. Mechanistically, this is due to an enhanced de novo lipogenesis, cholesterol biosynthesis and lipid uptake. Exogenous delivery of various lipids unveiled an altered maturation of lipid droplets in high-risk cells. Altogether, high-risk Group 3 and Group 4 Medulloblastoma cells use lipid droplets in response to excessive lipid synthesis, presenting a possible novel therapeutic target and prognostic marker.
- 5 October 2026
- Published by Springer Nature in Cell Death Discovery
Open AccessCholesterol esters in lipid droplets play a key role in the energy production of G3/G4 medulloblastoma cells
Medulloblastomas are the most common malignant paediatric brain tumours. High-risk subgroups, including MYC-driven Group 3, Group 4 and aggressive sonic hedgehog tumours, are refractory to current therapies and are associated with poor survival. The gold standard treatment comprises surgical resection with aggressive chemo and radiotherapy leading to severe developmental side effects, highlighting the requirement for novel approaches. Metabolic reprogramming is a crucial component of cancer progression with upregulated lipid metabolism being essential to support cancers survival in nutrient-deprived conditions. Lipid droplets are dynamic intracellular organelles protecting against lipotoxicity, yet their involvement in high-risk Medulloblastoma subgroups remains poorly understood. Here, we use transcriptomics and lipidomics of a panel of Medulloblastoma cells to understand the role of lipid metabolism. Our data shows that high-risk Medulloblastoma cells have increased numbers of lipid droplets and PLIN2 expression. This increased PLIN2 expression was consistent in human tissue microarray analysis. Mechanistically, this is due to an enhanced de novo lipogenesis, cholesterol biosynthesis and lipid uptake. Exogenous delivery of various lipids unveiled an altered maturation of lipid droplets in high-risk cells. Altogether, high-risk Group 3 and Group 4 Medulloblastoma cells use lipid droplets in response to excessive lipid synthesis, presenting a possible novel therapeutic target and prognostic marker.
- Open Access
- 30 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6519
ZNF750: A Novel Prognostic Biomarker in Metastatic Prostate Cancer
Prostate cancer is the most frequently diagnosed cancer and the fifth leading cause of cancer death among men in 2020. The clinical decision making for prostate cancer patients is based on the stratification of the patients according to both clinical and pathological parameters such as Gleason score and prostate-specific antigen levels. However, these tools still do not adequately predict patient outcome. The aim of this study was to investigate whether ZNF750 could have a role in better stratifying patients, identifying those with a higher risk of metastasis and with the poorest prognosis. The data reported here revealed that ZNF750 protein levels are reduced in human prostate cancer samples, and this reduction is even higher in metastatic samples. Interestingly, nuclear positivity is significantly reduced in patients with metastatic prostate cancer, regardless of both Gleason score and grade group. More importantly, the bioinformatics analysis indicates that ZNF750 expression is positively correlated with better prognosis. Overall, our findings suggest that nuclear expression of ZNF750 may be a reliable prognostic biomarker for metastatic prostate cancer, which lays the foundation for the development of new biological therapies.
- 30 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6519
Open AccessZNF750: A Novel Prognostic Biomarker in Metastatic Prostate Cancer
Prostate cancer is the most frequently diagnosed cancer and the fifth leading cause of cancer death among men in 2020. The clinical decision making for prostate cancer patients is based on the stratification of the patients according to both clinical and pathological parameters such as Gleason score and prostate-specific antigen levels. However, these tools still do not adequately predict patient outcome. The aim of this study was to investigate whether ZNF750 could have a role in better stratifying patients, identifying those with a higher risk of metastasis and with the poorest prognosis. The data reported here revealed that ZNF750 protein levels are reduced in human prostate cancer samples, and this reduction is even higher in metastatic samples. Interestingly, nuclear positivity is significantly reduced in patients with metastatic prostate cancer, regardless of both Gleason score and grade group. More importantly, the bioinformatics analysis indicates that ZNF750 expression is positively correlated with better prognosis. Overall, our findings suggest that nuclear expression of ZNF750 may be a reliable prognostic biomarker for metastatic prostate cancer, which lays the foundation for the development of new biological therapies.